Drugs / OTILONII BROMIDUM
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT05461833 Comparator | Sep 2020 → Dec 2021 | irritable bowel syndrome | Bogomolets National Medical University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTILONII BROMIDUM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05461833 ↗ |
| Route | Oral | “OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment” NCT05461833 ↗ |